investig
mechan
alvac
activ
innat
immun
combin
alvac
protein
antigen
significantli
augment
antigenspecif
respons
depend
presenc
bioactiv
interferon
ifn
immunodeplet
nk
cell
prior
alvac
immunis
abrog
product
indic
main
cellular
sourc
earli
vivo
murin
bonemarrow
deriv
dendrit
cell
bmdc
cultur
presenc
alvac
secret
high
level
chemokin
upregul
express
matur
marker
therefor
conclud
alvac
act
adjuv
mechan
requir
nk
cell
deriv
dc
activ
chemokin
secret
adjuv
improv
adapt
immun
respons
coinject
antigen
activ
innat
immun
spite
intens
research
still
limit
number
adjuv
avail
human
use
particular
enhanc
induct
polar
respons
requir
optimum
protect
immun
viral
infect
cancer
therapi
vaccin
strategi
base
canarypoxviru
vector
alvac
shown
potenti
infecti
diseas
cancer
alvac
larg
dna
viru
whose
replic
confin
avian
host
good
safeti
profil
human
despit
attenu
natur
alvac
caus
inflamm
site
inject
evidenc
infiltr
neutrophil
furthermor
previou
report
show
alvac
possess
adjuv
activ
studi
confirm
alvac
act
adjuv
enhanc
antigenspecif
coinject
protein
antigen
mice
intramuscular
im
inject
alvac
increas
level
circul
shortli
inject
alvac
enhanc
antigenspecif
respons
coinject
protein
antigen
receptor
knockout
mice
mice
indic
import
bioactiv
mediat
adjuv
effect
alvac
immunodeplet
nk
cell
dramat
impair
abil
alvac
induc
circul
indic
cell
major
produc
cytokin
vivo
previou
studi
shown
alvac
trigger
product
human
dc
interact
nk
dc
import
induct
innat
immun
respons
investig
effect
alvac
exposur
murin
bmdc
regard
matur
cytokin
product
show
experiment
condit
use
low
level
apoptosi
detect
alvac
induc
matur
dc
upregul
express
product
low
level
inflammatori
cytokin
howev
mark
increas
secret
chemokin
observ
therefor
lead
us
suggest
alvac
act
polar
adjuv
induc
local
inflamm
result
dc
matur
chemokin
product
turn
caus
recruit
secret
nk
cell
understand
mechan
adjuv
action
alvac
allow
effect
target
desir
immun
respons
take
advantag
fact
alvac
manipul
encod
varieti
immunomodulatori
transgen
eg
gmcsf
enhanc
activ
nk
cell
dc
six
eight
week
old
femal
balbc
byj
mice
charl
river
le
oncin
franc
receptor
knockout
receptor
knockout
b
k
univers
hull
uk
use
anim
hous
experi
carri
accredit
facil
guidelin
sanofipasteur
local
ethic
committe
studi
use
alvachiv
sanofipasteur
marci
letoil
franc
recombin
canarypox
vector
contain
gene
envelop
strain
mn
link
transmembran
portion
strain
lai
lai
gag
gene
encod
entir
gag
protein
sequenc
pol
gene
encod
proteas
synthet
polynucleotid
encompass
sever
known
human
ctl
epitop
nef
pol
gene
product
also
contain
sequenc
encod
vaccinia
viru
protein
site
alvac
placebo
sanofipasteur
contain
mixtur
mm
trishcl
buffer
ph
viru
stabil
freezedri
medium
alvac
placebo
reconstitut
steril
salin
prior
inject
recombin
hiv
tat
protein
iiib
isol
glycoprotein
b
gb
cytomegaloviru
cmv
purifi
bacteri
cultur
sanofipasteur
vaccin
use
studi
clinic
grade
verifi
free
lipopolysaccharid
lp
impur
group
balbc
knockout
knockout
mice
immunis
im
quadricep
follow
anaesthesia
imalgen
merial
lyon
franc
either
gb
gdose
tat
gdose
alon
combin
placebo
alvac
human
dose
mice
boost
day
serum
spleen
sampl
taken
day
antitat
gb
antibodi
titr
specif
cellular
respons
analys
describ
maxisorp
elisa
plate
nunc
wiesbaden
germani
coat
gml
either
tat
gb
pb
overnight
c
plate
block
nonfat
milk
gibco
paisley
uk
c
h
wash
serial
dilut
serum
sampl
standard
ad
h
c
plate
wash
detect
antibodi
goatantimous
igghrp
jackson
immunoresearch
laboratori
inc
west
grove
pa
ad
hour
c
plate
wash
tetramethlybenzidin
substrat
solut
ad
tebu
biolab
le
perrayenyvelin
franc
enzym
reaction
stop
addit
phosphor
acid
od
valu
nm
determin
antibodi
titr
calcul
linear
regress
curv
standard
specif
serum
origin
anim
speci
sampl
present
elisa
plate
softmax
softwar
tm
molecular
devic
sunnyval
ca
titr
standard
previous
determin
independ
experi
multiscreen
ht
plate
millipor
bedford
coat
overnight
c
captur
monoclon
antibodi
mab
clone
bd
pharmingen
san
diego
ca
wash
block
respond
spleen
cell
ad
concentr
cellswel
rpmi
gibco
supplement
fc
hyclon
logan
ut
penicillinstreptomycin
gibco
mm
lglutamin
gibco
mm
gibco
cell
stimul
triplic
gml
mer
tat
gag
peptid
neosystem
strasbourg
franc
medium
alon
neg
control
pma
sigmaaldrich
st
loui
mo
bd
pharmingen
posit
control
alvac
specif
immun
respons
measur
ad
cell
mous
lymphoblastlik
mastocytoma
cell
line
infect
multipl
infect
moi
parent
viru
cppp
overnight
cultur
incub
overnight
co
follow
day
detect
use
mab
clone
bd
pharmingen
follow
streptavidinhrp
southern
biotech
birmingham
al
visual
use
aec
substrat
sigmaaldrich
produc
spot
count
use
autom
elispot
reader
equip
spot
tm
softwar
microvis
instrument
evri
franc
alvac
abil
induc
earli
circul
follow
im
inject
evalu
use
vivo
detect
assay
describ
manufactur
bd
pharmingen
briefli
prior
im
inject
alvac
placebo
group
balbc
mice
given
intraperiton
ip
inject
gdose
mab
serum
sampl
remov
variou
timepoint
frozen
c
analysi
mab
complex
elisa
experi
nk
cell
deplet
use
antiasialo
polyclon
antibodi
cedarlan
laboratori
ontario
canada
ip
day
day
gdose
control
mice
receiv
dose
nonspecif
rabbit
igg
caltag
laboratori
burlingam
ca
captur
mab
either
placebo
alvac
inject
describ
serum
sampl
collect
h
postimmunis
frozen
c
analysi
elisa
spleen
remov
control
treat
anim
efficaci
nk
cell
deplet
measur
evalu
spleen
cell
express
nk
cell
marker
flow
cytometri
use
specif
mab
clone
bd
pharmingen
secret
cytokineschemokin
analyz
elisa
use
commerci
avail
match
pair
mab
murin
r
system
minneapoli
mn
murin
human
bd
pharmingen
san
diego
ca
limit
sensit
detect
pgml
elisa
assay
murin
detect
serum
sampl
use
commerci
avail
elisa
kit
instruct
endogen
rockford
il
detect
rang
assay
pgml
experi
cytokin
determin
perform
use
cytometr
bead
array
cba
mous
inflamm
kit
bd
pharmingen
describ
manufactur
sampl
acquir
bd
facscalibur
analys
cellquest
pro
tm
softwar
detect
rang
cytokin
method
pgml
bonemarrow
flush
femur
tibia
balbc
byj
mice
use
cold
complet
rpmi
cell
wash
resuspend
complet
rpmi
supplement
gmcsf
ngml
r
system
day
fresh
media
contain
gmcsf
ad
adher
cell
day
cell
wash
phenotyp
flow
cytometri
cell
use
experi
bmdc
cultur
concentr
cell
ml
complet
rpmi
h
presenc
alvac
moi
equival
volum
placebo
cell
cultur
medium
alon
use
neg
control
cell
cultur
toll
like
receptor
tlr
agonist
sanofipasteur
concentr
gml
posit
control
cell
wash
resuspend
pb
fc
nan
label
mab
specif
appropri
isotyp
control
bd
pharmingen
cell
acquir
use
facscalibur
bd
result
analyz
use
cellquest
pro
tm
softwar
bd
cell
death
analysi
either
human
peripher
blood
mononuclear
cell
pbmc
murin
bmdc
carri
use
tac
annexinvfitc
apoptosi
detect
kit
describ
manufactur
r
system
result
present
mean
sem
unless
otherwis
indic
differ
mean
multipl
group
experi
analys
use
oneway
anova
analysi
varianc
case
two
group
consid
result
analys
use
twotail
independ
variabl
student
test
analysi
perform
use
statview
softwar
sa
cari
nc
pvalu
consid
signific
group
balbc
mice
immunis
im
either
antigen
alon
tat
gb
combin
placebo
alvac
mice
receiv
booster
immunis
week
sacrif
week
later
order
investig
antigenspecif
immun
respons
titr
antigenspecif
igg
determin
elisa
level
gb
specif
igg
observ
group
receiv
gb
alvac
higher
group
receiv
gb
alon
group
immunis
gb
placebo
fig
similar
increas
antigenspecif
igg
observ
alvac
coinject
anoth
antigen
tat
fig
look
particular
subclass
igg
addit
alvac
antigen
tat
gb
caus
increas
level
antigenspecif
fig
howev
increas
observ
level
antigb
mice
receiv
gb
alvac
compar
mice
receiv
gb
alon
fig
similar
augment
tatspecif
observ
group
mice
receiv
tat
alvac
compar
receiv
either
tat
alon
tat
placebo
fig
result
clearli
show
alvac
act
adjuv
augment
antigenspecif
respons
coinject
antigen
next
investig
effect
alvac
cellular
immun
respons
coinject
antigen
group
balbc
mice
immunis
tat
alon
tat
placebo
tat
alvac
week
booster
immunis
mice
sacrif
spleen
remov
analys
cellular
immun
respons
spleen
cell
restimul
vitro
number
antigenspecif
secret
cell
determin
elispot
fig
number
tatspecif
secret
cell
group
mice
receiv
tat
alon
tat
placebo
significantli
differ
background
level
fig
howev
tatspecif
secret
cell
detect
group
receiv
tat
togeth
alvac
secret
cell
specif
vector
cppp
gag
encod
alvac
detect
group
receiv
alvac
fig
data
show
alvac
augment
humor
cellular
type
respons
coinject
antigen
two
major
signal
pathway
particip
innat
immun
respons
viral
dna
name
nuclear
factorb
nfb
depend
pathway
lead
inflammatori
cytokin
secret
includ
type
ifndepend
pathway
induc
ifnregul
gene
therefor
wish
determin
andor
produc
vivo
follow
inject
alvac
group
balbc
mice
immunis
simultan
im
rout
human
dose
alvac
ip
biotinconjug
mab
subsequ
mice
bled
variou
timepoint
immunis
level
mab
complex
determin
elisa
signific
quantiti
detect
circul
mice
h
immunis
fig
mab
complex
continu
accumul
circul
alvac
immunis
mice
h
postimmunis
fig
antibodi
stabl
h
vivo
use
human
dose
result
less
circul
human
dose
illustr
effect
dosedepend
fig
order
detect
circul
group
balbc
mice
immunis
im
human
dose
alvac
bled
variou
timepoint
level
serum
determin
elisa
low
transient
amount
could
detect
h
serum
alvac
immunis
mice
fig
summari
alvac
immunis
induc
low
amount
signific
amount
differ
kinet
earli
transient
appear
later
sustain
howev
use
vivo
captur
assay
determin
circul
amount
stabl
mab
complex
straightforward
elisa
approach
detect
rel
labil
draw
conclus
rel
import
two
cytokin
adjuvant
alvac
data
variou
time
point
serum
sampl
prepar
mice
frozen
c
analysi
level
complex
mab
determin
elisa
use
standard
curv
gener
use
recombin
preincub
biotinyl
mab
result
express
mean
cytokin
concentr
standard
deviat
p
p
ns
signific
b
separ
experi
group
balbc
mice
per
group
immunis
placebo
alvac
human
dose
time
serum
sampl
remov
variou
timepoint
frozen
c
analysi
level
serum
determin
elisa
triplic
serum
pool
group
result
express
mean
cytokin
concentr
standard
error
demonstr
alvac
could
induc
innat
albeit
differ
amount
vari
kinet
wish
address
question
whether
induct
one
cytokin
crucial
adjuv
activ
alvac
order
immunis
group
wild
type
mice
either
gb
placebo
gb
alvac
evalu
gb
specif
immun
respons
approach
enabl
us
observ
alvac
maintain
adjuv
properti
absenc
bioactiv
antigb
specif
igg
level
similar
group
mice
irrespect
mous
genotyp
vaccin
fig
antigb
specif
level
margin
reduc
group
receiv
gb
alvac
compar
anim
boost
day
serum
sampl
taken
day
antigb
specif
igg
b
c
titr
determin
elisa
result
repres
mean
standard
deviat
mice
per
group
p
ns
signific
antigb
specif
ratio
determin
valu
indic
equal
amount
antigenspecif
produc
valu
greater
indic
antispecif
valu
less
one
signifi
receiv
gb
placebo
genotyp
fig
howev
clear
augment
gb
specif
observ
mice
receiv
gb
alvac
compar
gb
placebo
contrast
signific
increas
antigb
observ
mice
upon
addit
alvac
protein
antigen
fig
data
indic
although
alvac
induc
innat
product
vivo
dispens
augment
specif
coinject
antigen
nk
cell
major
cellular
sourc
produc
first
phase
immun
respons
infect
order
determin
role
innat
immun
respons
alvac
deplet
nk
cell
balbc
mice
measur
abil
mice
produc
respons
im
inject
alvac
nk
cell
deplet
achiev
use
two
dose
polyclon
ab
one
given
day
second
togeth
alvac
inject
efficaci
deplet
illustr
lack
nk
cell
specif
marker
balbc
mice
express
cell
spleen
treat
mice
compar
mice
treat
isotyp
control
antibodi
fig
group
mice
either
nk
cell
deplet
immunis
placebo
alvac
given
simultan
ip
inject
day
mice
sacrif
serum
analys
level
circul
mab
complex
elisa
found
induct
circul
alvac
significantli
reduc
follow
nk
cell
deplet
fig
indic
nk
cell
fig
alvac
induct
circul
innat
depend
upon
presenc
nk
cell
nk
cell
deplet
balbc
mice
use
polyclon
antiasialo
antibodi
mice
inject
ip
g
antibodi
day
day
rabbit
igg
use
isotyp
control
day
biotinyl
gdose
given
ip
anim
variou
group
immunis
im
either
placebo
alvac
human
dose
serum
sampl
prepar
day
level
circul
antibodi
complex
determin
elisa
valu
shown
mean
standard
deviat
mice
per
group
p
ns
signific
b
treatment
ab
reduc
cell
spleen
treat
mice
control
treat
group
treat
group
averag
micetreat
group
standard
deviat
spleen
cell
isol
mice
per
group
express
determin
flow
cytometri
use
pelabel
specif
mab
quadrant
determin
stain
isotyp
control
antibodi
repres
fac
plot
per
treatment
shown
primari
sourc
secret
respons
alvac
within
first
h
immunis
activ
dc
augment
product
nk
cell
therefor
wish
investig
exposur
alvac
activ
dc
order
alvac
act
effect
vaccin
vector
must
infect
host
cell
order
produc
antigen
integr
genom
howev
examin
adjuv
effect
alvac
interest
investig
immunomodulatori
effect
expos
cell
alvac
without
necessarili
becom
infect
addit
vitro
infect
protocol
use
low
serum
condit
high
moi
shown
induc
apoptosi
target
cell
preliminari
experi
show
moi
induc
signific
cell
death
murin
bonemarrow
deriv
dc
bmdc
cultur
period
h
data
shown
murin
bmdc
cultur
h
concentr
cellsml
complet
rpmi
supplement
fc
alon
addit
alvac
moi
equival
volum
placebo
agonist
posit
control
cell
stain
fluoresc
label
mab
specif
costimulatori
molecul
express
level
analys
flow
cytometri
percentag
bmdc
express
costimulatori
molecul
significantli
increas
follow
exposur
alvac
compar
medium
alon
placebo
fig
howev
enhanc
costimulatori
molecul
express
induc
alvac
weaker
observ
follow
stimul
bmdc
agonist
fig
nonetheless
data
illustr
exposur
alvac
activ
dc
activ
dc
secret
inflammatori
cytokin
chemokin
recruit
activ
cell
innat
adapt
immun
respons
respons
alvac
low
amount
proinflammatori
cytokin
produc
dc
gener
amount
less
induc
agonist
use
posit
control
experi
fig
howev
level
chemokin
produc
bmdc
follow
incub
alvac
exceed
equival
induc
agonist
fig
b
secret
bmdc
detect
respons
alvac
fig
order
reap
optimum
benefit
therapeut
immunis
strategi
cancer
chronic
viral
infect
vaccin
need
formul
way
augment
effector
arm
immun
respons
report
show
alvac
act
polar
adjuv
mous
model
fig
show
bioactiv
crucial
adjuv
effect
antigenspecif
respons
coinject
protein
enhanc
mice
mice
fig
immunodeplet
nk
cell
reveal
import
sourc
innat
produc
respons
alvac
inject
vivo
fig
furthermor
show
stimul
murin
bmdc
alvac
vitro
induc
dc
matur
fig
chemokin
secret
particularli
fig
b
addit
alvac
inject
result
enlarg
local
drain
lymph
node
poplit
follow
im
inject
data
shown
therefor
conclud
alvac
inject
activ
innat
immun
respons
enhanc
induct
respons
coinject
antigen
recombin
alvac
use
studi
shown
well
toler
clinic
trial
previou
report
shown
alvac
act
adjuv
particular
boudet
et
al
show
purifi
alvac
either
infecti
noninfecti
form
adjuv
effect
coadminist
recombin
hiv
antigen
result
increas
antigenspecif
igg
mice
guinea
pig
hutch
et
al
further
show
adjuv
activ
common
poxvirus
nyvac
fowlpox
well
alvac
poxvirus
nyvac
fowlpox
alvac
lesser
extent
adenoviru
enhanc
immun
respons
coinject
recombin
hepat
b
surfac
antigen
hbsag
interestingli
combin
nonrecombin
alvac
vector
hbsag
induc
strongest
antigenspecif
cellular
respons
drain
lymph
node
compar
respons
result
includ
poxviru
vector
investig
two
major
tlr
mediat
signal
pathway
particip
respons
pathogen
nuclearfactor
b
nfb
depend
pathway
lead
secret
inflammatori
cytokin
type
ifn
pathway
synergis
nfb
pathway
optim
secret
show
inject
alvac
result
increas
level
circul
fig
b
order
determin
induct
one
cytokin
crucial
adjuv
effect
alvac
immunis
wild
type
mice
gb
cmv
either
without
alvac
mice
receiv
gb
alvac
produc
higher
titr
gb
specif
compar
group
receiv
gb
placebo
fig
indic
bioactiv
dispens
adjuv
effect
alvac
studi
investig
immunogen
adenoviru
vector
demonstr
although
type
ifn
signal
import
compon
adenovirusmedi
dc
matur
dispens
gener
transgen
product
specif
cell
respons
therefor
appear
although
induc
alvac
may
well
play
role
augment
innat
immun
respons
requir
adjuv
effect
activ
nk
cell
secret
larg
amount
respons
pathogen
activ
dc
order
determin
produc
respons
immunis
alvac
fig
produc
nk
cell
immunis
nk
cell
deplet
mice
alvac
determin
level
circul
fig
produc
respons
alvac
nk
celldeplet
mice
significantli
lower
observ
mice
treat
isotyp
control
indic
nk
cell
signific
sourc
produc
recent
report
alvac
preferenti
infect
human
cell
monocyt
lineag
infact
unabl
infect
human
nk
cell
vitro
data
indic
mous
model
nk
cell
play
crucial
role
mediat
inflammatori
respons
alvac
studi
human
cell
vitro
ex
vivo
requir
determin
role
nk
cell
innat
respons
alvac
follow
vaccin
man
recent
becom
clear
import
bidirect
dialogu
dc
nk
cell
review
tlrdepend
microbi
stimuli
typic
associ
respons
confer
dc
abil
activ
nk
cell
secret
directli
induc
nk
cell
abil
lyse
immatur
dc
discoveri
human
nk
cell
express
suggest
exist
tlrbase
nk
celldc
crosstalk
might
relev
explain
nk
cell
dc
activ
simultan
pathogen
build
effici
innat
immun
respons
amplifi
downstream
adapt
respons
previou
report
show
matur
immatur
human
dc
could
success
infect
alvac
mani
alvac
infect
immatur
dc
rapidli
underw
apoptosi
endocytosi
infect
dead
die
dc
uninfect
immatur
dc
observ
concurr
subpopul
alvacexpos
dc
matur
matur
driven
secret
follow
exposur
alvac
partial
ingest
infect
cell
debri
investig
effect
expos
murin
bmdc
alvac
vitro
found
exposur
h
moi
condit
induc
signific
amount
apoptosi
activ
dc
evidenc
upregul
costimulatori
molecul
fig
addit
exposur
alvac
induc
murin
bmdc
secret
signific
quantiti
chemokin
fig
chemotact
cell
nk
cell
express
play
role
recruit
monocytesmacrophag
interact
recent
studi
neutralis
antibodi
mice
demonstr
absenc
function
result
increas
mortal
reduc
cell
infiltr
within
brain
mice
infect
intracerebr
murin
coronaviru
illustr
import
chemokin
coordin
protect
immun
respons
viral
pathogen
interact
import
factor
promot
earli
inflammatori
respons
effect
local
antivir
defens
abil
alvac
induc
dc
secret
chemokin
may
provid
signal
requir
nk
cell
migrat
dcrich
area
bring
close
proxim
enabl
direct
cellcel
contact
therebi
result
downstream
respons
found
signific
increas
size
cellular
local
drain
lymph
node
follow
inject
alvac
data
shown
use
flow
cytometr
analysi
lymph
node
cell
could
determin
chang
cell
type
data
shown
data
conjunct
previou
work
boudet
et
al
demonstr
alvac
trigger
inflammatori
respons
induc
migrat
neutrophil
site
inocul
within
h
administr
enlarg
local
drain
lymph
node
therefor
propos
follow
mechan
adjuvant
alvac
alvac
caus
inflamm
pmn
recruit
site
inject
turn
caus
activ
local
dc
demonstr
increas
costimulatori
molecul
express
cell
may
migrat
local
drain
lymph
node
dc
secret
chemokin
includ
caus
influx
cell
includ
nk
cell
interact
dc
nk
cell
local
lymph
node
trigger
secret
nk
cell
result
increas
cell
specif
coadminist
protein
cell
recircul
b
cell
rich
area
spleen
enhanc
isotyp
switch
